Aligos Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2018-04-12
- Employees
- 66
- Market Cap
- -
- Website
- http://www.aligos.com
- Introduction
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
- Conditions
- Chronic Hepatitis B Infection
- Interventions
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT06963710
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT06959888
- Locations
- πΊπΈ
PPD Austin CRU, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06698549
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈGenesis Clinical Trials, Tampa, Florida, United States
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT06672900
- Locations
- πΊπΈ
PPD Austin Research Unit, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT06568861
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
- Conditions
- NASHNonalcoholic SteatohepatitisMASHMetabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 102
- Registration Number
- NCT06342947
- Locations
- πΊπΈ
Aligos Clinical Study Site 11, Waco, Texas, United States
πΊπΈAligos Clinical Study Site 18, Chandler, Arizona, United States
πΊπΈAligos Clinical Study Site 3, Viera, Florida, United States
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT06191991
- Locations
- πΊπΈ
PPD Austin Research Unit, Austin, Texas, United States
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: ALG-097558 in solution formulationDrug: ALG-097558 in tablet formulation
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT05840952
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT05561530
- Locations
- π§π¬
MBAL Sveta Sofia EOOD, Dept of Internal Medicine with Gastroenterology Section, Sofia, Bulgaria
π²π©PMSI Republican Clinical Hospital "t. Mosneaga", ARENSIA Exploratory Medicine Phase 1 Unit, Chisinau, Moldova, Republic of
π³πΏNew Zealand Clinical Research, Auckland, New Zealand
A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT05090111
- Locations
- π«π·
Biotrial, Rennes, France